PeptiDream slashes 2025 forecasts due to partnership delays

PeptiDream announced a substantial revision to its consolidated financial forecasts for the fiscal year ending December 31, 2025. The company now anticipates revenue of 18,000 million yen, a sharp decrease from the previously projected 49,000 million yen. This adjustment also led to significant revisions across profitability metrics, with core operating profit now projected at (5,300) million yen, operating profit at (5,400) million yen, profit before tax at (5,800) million yen, and profit attributable to owners of parent at (4,000) million yen.

The primary reason for the revision stems from the delayed consummation of anticipated partnership deals and development milestones. Specifically, the licensing of PeptiDream's oral myostatin program, a major contributor to earlier revenue forecasts, is now unlikely to be finalized within FY2025 due to ongoing negotiations and time constraints. Additionally, other collaboration-related milestones and business deals originally expected in FY2025 are now projected to occur in FY2026.

Despite these financial revisions, PeptiDream emphasized its continued progress in pipeline development, highlighting four partnered RI-PDC programs advancing into clinical development, the PSMA program initiating registrational clinical trials in Japan, and IND filings in the US for diagnostic and therapeutic CA9 programs. The company will provide a detailed update on its clinical pipeline at an upcoming R&D Day on December 5, 2025.